AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 12940804
Drug: Fixed combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed combination of indomethacin, prochlorperazine, and caffeine
Trial: 10613779
Drug: Antibiotic treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic treatments
Trial: 10613779
Drug: Various therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various therapies
Trial: 9327254
Drug: Behavioral medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral medicine intervention (6-week duration)
Trial: 3468098
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg ofloxacin by mouth once daily for ten days
Trial: 3468098
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg ofloxacin by mouth twice daily for ten days
Trial: 3468098
Drug: Concomitantly administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concomitantly administered theophylline
Trial: 27234663
Drug: Weekly PST
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly PST (n=1465)
Trial: 27234663
Drug: Monthly HQACM
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly HQACM (n=1457)
Trial: 27234663
Drug: PST twice
RxNorm normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PST twice weekly (n=118)
Trial: 14682413
Drug: Inhaled budesonide
RxNorm normalized name: budesonide Inhalation Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled budesonide 400 microg once daily
Trial: 14682413
Drug: Oral montelukast
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral montelukast 10 mg once daily
Trial: 8897759
Drug: 10 million
RxNorm normalized name: Interferon Alfa-2b 10 MILLION IU/1 ML Injection Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 million units of IFN-alpha 2b daily for 2 weeks
Trial: 8897759
Drug: 10 million
RxNorm normalized name: Interferon Alfa-2b 10 MILLION IU/1 ML Injection Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 million units of IFN-alpha 2b twice a week for 24 weeks
Trial: 26356548
Drug: RPA training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RPA training (leg-press exercise, twice a week for 6 weeks, 1 or 2 blocks of 5 sets × 5 repetitions with 20 s of passive recovery between sets and 3 min between blocks)
Trial: 16350679
Drug: Combined supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined supplementation of fish oil (600 mg) with garlic pearls (500 mg) per day for 60 days
Trial: 2570701
Drug: cetirizine diHCl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cetirizine diHCl 10 mg
Trial: 28957407
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no treatment prior to RCT)
Trial: 25986641
Drug: Health consultation
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Health consultation involving a self-help manual, monthly prompts, and spirometry
Trial: 23892341
Drug: Intravenous hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous hydrocortisone 250 mg (steroid group)
Trial: 17197377
Drug: Immediate substitution
RxNorm normalized name: hydroxypropyl cellulose, low substituted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate substitution with lopinavir/ritonavir 400/100 mg bid
Trial: 1926985
Drug: Benazepril (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benazepril (10 mg bid)
Trial: 6126170
Drug: THIP (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: THIP (10 to 25 mg single dose; 20 to 120 mg daily for four weeks)
Trial: 29341471
Drug: Maximal tolerated
RxNorm normalized name: Spirulina maxima preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maximal tolerated dose of valsartan (titrated up to 320 mg/day, n=333)
Trial: 29341471
Drug: Low-dose valsartan
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose valsartan (80 mg/day, n=162)
Trial: 29341471
Drug: Maximal tolerated
RxNorm normalized name: Spirulina maxima preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maximal tolerated dose of valsartan (titrated up to 320 mg/day)
Trial: 29341471
Drug: Low-dose valsartan
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose valsartan (80 mg/day)
Trial: 22174029
Drug: Atomoxetine (Atx)
DrugBank: Atomoxetine (DB00289)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atomoxetine (Atx) 80 mg daily for 12 weeks
Trial: 10084468
Drug: Ipratropium plus
RxNorm normalized name: Ipratropium
DrugBank: Ipratropium (DB00332)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ipratropium plus Albuterol
Trial: 10084468
Drug: Ipratropium plus
RxNorm normalized name: Ipratropium
DrugBank: Ipratropium (DB00332)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ipratropium plus Albuterol and Ipratropium
Trial: 7604808
Drug: Acute alcohol
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acute alcohol consumption (70 g of ethanol diluted to 20% with lemonade)
Trial: 2195934
Drug: Colchicine 0.6
RxNorm normalized name: colchicine 0.6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colchicine 0.6 mg three times per day for 14 days
Trial: 22766970
Drug: Fractional CO(2)
RxNorm normalized name: CO
DrugBank: Carbon monoxide (DB11588)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fractional CO(2) laser treatments (3 monthly sessions, MedArt 610; 12-14 W, 48-56 mJ/pulse, 13% density)
Trial: 12016098
Drug: Theophylline (plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline (plasma level of 9-11 mg/L) for 4 weeks
Trial: 346628
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment (cat pelt extract)
Trial: 31362784
Drug: Bupropion (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupropion (300 mg per day)
Trial: 27632069
Drug: Lactated Ringer
RxNorm normalized name: lactated ringers
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lactated Ringer solution (LR; placebo)
Trial: 27632069
Drug: Nonsteroidal anti-inflammatory
RxNorm normalized name: Surpass Anti-Inflammatory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonsteroidal anti-inflammatory drugs (NSAIDs) use
Trial: 26502867
Drug: Casperome® 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Casperome® 500 mg/day
Trial: 23810644
Drug: Topiramate, 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topiramate, 300 mg daily
Trial: 21543963
Drug: 16 g
RxNorm normalized name: Maltsupex, 16 g/15 mL oral liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16 g total dietary fiber per day from psyllium
Trial: 21543963
Drug: Steady dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steady dose segment (all fiber sources)
Trial: 17456571
Drug: Cabergoline (Cb2)
RxNorm normalized name: Cabergoline
DrugBank: Cabergoline (DB00248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cabergoline (Cb2) 0.5 mg/d
Trial: 29519777
Drug: Internet-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based cognitive behavioral therapy (iCBT) for 14 weeks (n=117)
Trial: 29519777
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (TAU) (n=122)
Trial: 26338889
Drug: Dal (lentils
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dal (lentils enriched to 85.1% with (57)Fe, 8 mg native (57)Fe)
Trial: 26338889
Drug: Ferrous sulfate
RxNorm normalized name: Ferrous Sulfate
DrugBank: Ferrous fumarate (DB14491)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ferrous sulfate (7 mg FeSO4 plus 1 mg (58)Fe)
Trial: 8427539
Drug: Clarithromycin 500
RxNorm normalized name: clarithromycin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin 500 or 1000 mg daily (n = 21)
Trial: 8427539
Drug: Clarithromycin 1500
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clarithromycin 1500 or 2000 mg daily (n = 56)
Trial: 8427539
Drug: Continuous treatment
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous treatment with clarithromycin
Trial: 8427539
Drug: Stopped treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stopped treatment for 7 days or longer
Trial: 8427539
Drug: Concomitant AIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concomitant AIDS drugs
Trial: 24299021
Drug: Montelukast treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montelukast treatment for 3 months
Trial: 14509153
Drug: Garlic (alliin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Garlic (alliin 22.4 mg/day)
Trial: 7590497
Drug: Desferrioxamine (DFO)
RxNorm normalized name: DFO
DrugBank: Deferoxamine (DB00746)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Desferrioxamine (DFO) at a dose of 40 mg/kg/day as a 24-hour intravenous infusion from day -9 to day +60
Trial: 2671247
Drug: Intensified conventional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensified conventional insulin treatment (ICT)
Trial: 1101904
Drug: Chlordiazepoxide 10
RxNorm normalized name: chlordiazepoxide 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlordiazepoxide 10 mg t.i.d.
Trial: 1101904
Drug: Flupenthixole 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flupenthixole 0.5 mg t.i.d.
Trial: 1101904
Drug: Chlordiazepoxide with
RxNorm normalized name: Chlordiazepoxide
DrugBank: Chlordiazepoxide (DB00475)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chlordiazepoxide with alcohol (0.5 g/kg)
Trial: 1101904
Drug: Flupenthixole with
RxNorm normalized name: flupenthixol
DrugBank: Flupentixol (DB00875)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flupenthixole with alcohol (0.5 g/kg)
Trial: 30829050
Drug: OTO-201 (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OTO-201 (0.2 mL, 12 mg, n = 130)
Trial: 30829050
Drug: Sham (air
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham (air injection, n = 130)
Trial: 24254557
Drug: 1 cc
RxNorm normalized name: BD Needle SG 1 cc 27g 5/8"
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 cc 1% lidocaine before biopsy
Trial: 21270143
Drug: Oral antipsychotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral antipsychotic regimen selected by control patient's psychiatrist
Trial: 19091331
Drug: 200 microg
RxNorm normalized name: Digoxin 200 microgram oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 microg selenium orally daily (selenium group of 116)
Trial: 19091331
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg N-acetyl-cysteine orally daily (N-acetyl-cysteine group of 118)
Trial: 19091331
Drug: 200 microg
RxNorm normalized name: Digoxin 200 microgram oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 microg selenium plus 600 mg N-acetyl-cysteine orally daily (selenium plus N-acetyl-cysteine group of 116)
Trial: 11310696
Drug: Administration of
RxNorm normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of blood products through central venous catheters
Trial: 3773728
Drug: 30 IU/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 IU/kg heparin
Trial: 20562076
Drug: 50 IU/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 IU/kg heparin
Trial: 3773728
Drug: 75 IU/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 IU/kg heparin
Trial: 3773728
Drug: 100 IU/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 IU/kg heparin
Trial: 3773728
Drug: Repeated daily
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeated daily injections of 75 IU/kg heparin
Trial: 3773728
Drug: Infusion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of heparin or saline on three consecutive days
Trial: 26963689
Drug: Aripiprazole (started
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aripiprazole (started at 2 mg daily, titrated to a maximum of 15 mg daily)
Trial: 26963689
Drug: Placebo (started
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (started at 2 mg daily, titrated to a maximum of 15 mg daily)
Trial: 20386995
Drug: Double-blind cyclical
RxNorm normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double-blind cyclical alternative medications for osteoarthritis
Trial: 20386995
Drug: Double-blind cyclical
RxNorm normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double-blind cyclical alternative medications for chronic neuropathic pain
Trial: 20386995
Drug: Double-blind cyclical
RxNorm normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double-blind cyclical alternative medications for ADHD
Trial: 18469572
Drug: Inhaled salbutamol
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inhaled salbutamol 800 microg
Trial: 18469572
Drug: Inhaled salbutamol
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inhaled salbutamol 400 microg
Trial: 18469572
Drug: Inhaled salbutamol
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inhaled salbutamol 200 microg
Trial: 18320340
Drug: Short-term desmopressin
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term desmopressin (0.2 mg for first 3 weeks, 0.4 mg for following 3 weeks) plus 12 weeks of enuretic alarm therapy
Trial: 18320340
Drug: Enuretic alarm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enuretic alarm therapy alone for 12 weeks
Trial: 18320340
Drug: Short-term desmopressin
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term desmopressin plus alarm therapy
Trial: 15029120
Drug: Antibacterial drug
RxNorm normalized name: Dermoplast Antibacterial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibacterial drug treatment with sumamed
Trial: 15029120
Drug: Antibacterial drug
RxNorm normalized name: Dermoplast Antibacterial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibacterial drug treatment with rulid
Trial: 15029120
Drug: Antibacterial drug
RxNorm normalized name: Dermoplast Antibacterial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibacterial drug treatment with clindamycin
Trial: 24734423
Drug: 1 ml
RxNorm normalized name: ethanol 1 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 ml of liquid probiotic Enterococcus faecium L3 (5x10(8) CFU/ml) 2 times a day for 10 days (mature infants)
Trial: 24734423
Drug: 1 ml
RxNorm normalized name: ethanol 1 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 ml of liquid probiotic Enterococcus faecium L3 (5x10(8) CFU/ml) 2 times a day for 10 days (premature infants)
Trial: 24734423
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (mature infants)
Trial: 24734423
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (premature infants)
Trial: 21788265
Drug: Short-term practice
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term practice group (1 treatment protocol over 4 weeks)
Trial: 19326288
Drug: Melatonin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin (2 mg prolonged-release preparation, CircadinTM)
Trial: 15619134
Drug: Methylene blue
RxNorm normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylene blue (130 mg twice daily for 3 days)
Trial: 11703885
Drug: Tolterodine 4
RxNorm normalized name: tolterodine 4 mg oral capsule, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolterodine 4 mg extended-release daily
Trial: 11703885
Drug: Tolterodine (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolterodine (various doses)
Trial: 11703885
Drug: Oxybutynin 5
RxNorm normalized name: oxyBUTYnin 5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxybutynin 5 mg tid
Trial: 8484548
Drug: Propofol induction
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol induction followed by propofol infusion and nitrous oxide (Group 2)
Trial: 3547179
Drug: Diacereine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diacereine (100 mg/die for 4 weeks)
Trial: 3547179
Drug: Diacereine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diacereine (100 mg/die for 2 weeks)
Trial: 3547179
Drug: Diacereine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diacereine (100 mg/die 5 days a week for 12 weeks)
Trial: 27531238
Drug: Hybrid of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hybrid of intracavitary and interstitial brachytherapy (HBT) with 30‐30.6 Gy in 15‐17 fractions of whole pelvic radiotherapy concurrent with weekly CDDP (40 mg/m(2)), followed by 24 Gy in 4 fractions of HBT and central shield EBRT up to 50‐50.4 Gy in 25‐28 fractions.
Trial: 18655753
Drug: Placebo (saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (saline solution; n = 32)
Trial: 16428155
Drug: Butenafine once
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Butenafine once daily for 2 weeks
Trial: 16428155
Drug: Clotrimazole twice
RxNorm normalized name: Clotrimazole
DrugBank: Clotrimazole (DB00257)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clotrimazole twice daily for 4 weeks
Trial: 12114432
Drug: Cisplatin (CDDP)
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin (CDDP) 100 mg/m2 on day 1 plus Gemcitabine (Gem) 1250 mg/m2 on days 1 and 8 every 3 weeks
Trial: 2351364
Drug: Neurotropin tablets
RxNorm normalized name: neurotrophin 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neurotropin tablets
Trial: 385518
Drug: V. F.
RxNorm normalized name: Vancomycin Hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: V. F. (peptides from bovine Factor VIII) administered at 1 mg/day in two oral doses
Trial: 25500935
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg Cortef (glucocorticoids) administered orally in the late afternoon for 6 days
Trial: 17117395
Drug: memantine (titrated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: memantine (titrated to 20 mg)
Trial: 15569113
Drug: Pantoprazole (10,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pantoprazole (10, 20, or 40 mg daily)
Trial: 15569113
Drug: Pantoprazole (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pantoprazole (20 or 40 mg daily)
Trial: 15569113
Drug: Nizatidine (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nizatidine (150 mg b.d.)
Trial: 8002638
Drug: UFT (uracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UFT (uracil and tegafur) 400 mg/day for 1 year
Trial: 2790692
Drug: CT +
RxNorm normalized name: Aveeno Protect + Hydrate SPF70 Lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CT + RT (Continuous 5-FU infusion followed by hepatic irradiation of 25.5 Gy)
Trial: 2790692
Drug: CT (Continuous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CT (Continuous 5-FU infusion)
Trial: 801578
Drug: Fentanyl (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl (0.1 mg reinjection)
Trial: 801578
Drug: Sulfentanil (0.01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulfentanil (0.01 mg reinjection)
Trial: 801578
Drug: Fentanyl (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl (0.5 mg reinjection)
Trial: 801578
Drug: Sulfentanil (0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulfentanil (0.05 mg reinjection)
Trial: 801578
Drug: Fentanyl (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl (0.1 mg reinjection) with droperidol (1.25 mg)
Trial: 801578
Drug: Sulfentanil (0.01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulfentanil (0.01 mg reinjection) with droperidol (1.25 mg)
Trial: 17903073
Drug: Combined continuous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined continuous ethinyl estradiol (10 microg) and norethindrone acetate (1 mg) given once daily for 3 months
Trial: 16131023
Drug: Yogurt supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yogurt supplementation (125 g, 5 days a week for 9 months)
Trial: 1942990
Drug: bemitil (0.25‐0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bemitil (0.25‐0.5 g/day orally for 5‐7 days)
Trial: 7452507
Drug: Naltrexone (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone (50 mg/day p.o.)
Trial: 6520821
Drug: Short course
RxNorm normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short course of intravenous cefoxitin prophylaxis and intraoperative saline irrigation